Aberdeen Group’s Takeda Pharmaceutical TAK Stock Holding History

Aberdeen Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-105,073	Closed	-$1.56M	–	975
2025 Q1	$1.56M	Hold	105,073	–	–	﹤0.01%	783
2024 Q4	$1.38M	Hold	105,073	–	–	﹤0.01%	795
2024 Q3	$1.49M	Hold	105,073	–	–	﹤0.01%	783
2024 Q2	$1.36M	Hold	105,073	–	–	﹤0.01%	794
2024 Q1	$1.46M	Hold	105,073	–	–	﹤0.01%	802
2023 Q4	$1.5M	Buy	+105,073	New	+$1.49M	﹤0.01%	799
2019 Q2	–	Sell	-469,199	Closed	-$9.56M	–	937
2019 Q1	$9.56M	Buy	+469,199	New	+$9.44M	0.02%	515

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Aberdeen Group's TAK Position: Q2 2025 in Review

Aberdeen Group sold out of Takeda Pharmaceutical (TAK) in Q2 2025, closing a stake of 105,073 shares — an estimated $1.56M sold.

Aberdeen Group first reported a position in TAK in Q1 2019 and held it in 7 quarters. The position peaked at $9.56M in Q1 2019. 315 funds tracked by Wall St. Rank hold TAK as of Q2 2025.

Aberdeen Group reported no remaining Takeda Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Aberdeen Group sold 105,073 Takeda Pharmaceutical shares in Q2 2025, an estimated $1.56M.
Aberdeen Group first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 7 quarters.
Aberdeen Group's Takeda Pharmaceutical position peaked at $9.56M in Q1 2019.
315 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2025.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.